Clinical Trials Browser

NCT07477587 2026-03-17

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

Phase 1 Not yet recruiting

258 enrolled

Plasma cell

Multiple Myeloma

NCT04579523 2026-03-13

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Phase 1 Not yet recruiting

30 enrolled

Plasma cell

Multiple Myeloma

NCT07297160 2026-03-04

CALySSEY

Phase 1 Not yet recruiting

88 enrolled

GenitourinaryLymphoidOther hematologic neoplasmPlasma cellSarcoma

Kidney Neoplasms, Lymphoma, Sarcoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT07082270 2026-02-19

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

Phase 1 Not yet recruiting

21 enrolled

Plasma cell

Multiple Myeloma

NCT07409246 2026-02-13

A Study to Evaluate the, Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

Phase 1 Not yet recruiting

127 enrolled

Plasma cell

Multiple Myeloma, Neoplasms

NCT07407010 2026-02-12

CM336-001

Phase 1 Not yet recruiting

10 enrolled

Plasma cell

Multiple Myeloma

NCT07400744 2026-02-10

A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects

Phase 1 Not yet recruiting

102 enrolled

Plasma cell

Multiple Myeloma

NCT07377435 2026-01-29

DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM

Phase 1 Not yet recruiting

25 enrolled

Plasma cell

Multiple Myeloma

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Phase 1 Not yet recruiting

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT07255898 2025-12-01

A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Phase 1 Not yet recruiting

33 enrolled

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT07221032 2025-10-27

FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

Phase 1 Not yet recruiting

12 enrolled

Plasma cell

Multiple Myeloma

NCT07200089 2025-09-30

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

Phase 1 Not yet recruiting

40 enrolled

Plasma cell

Multiple Myeloma

NCT06698744 2025-09-23

UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Not yet recruiting

12 enrolled

Plasma cell

Multiple Myeloma

NCT07113496 2025-08-13

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Phase 1 Not yet recruiting

27 enrolled

LymphoidPlasma cell

Plasmablastic Lymphoma, Burkitt Lymphoma, Multiple Myeloma, Recurrence

NCT07114432 2025-08-11

RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma

Phase 1 Not yet recruiting

19 enrolled

Plasma cell

Multiple Myeloma

NCT07032714 2025-06-26

MAGENTA

Phase 1 Not yet recruiting

25 enrolled

Plasma cell

Multiple Myeloma

NCT05976555 2025-06-11

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Phase 1 Not yet recruiting

30 enrolled

Plasma cell

Multiple Myeloma

NCT06913179 2025-04-06

CAR-T-allo

Phase 1 Not yet recruiting

30 enrolled

Plasma cell

Multiple Myeloma

NCT06913192 2025-04-06

AUTO-CAR-T

Phase 1 Not yet recruiting

50 enrolled

Plasma cell

Multiple Myeloma

NCT06705725 2024-11-26

Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma

Phase 1 Not yet recruiting

38 enrolled

Plasma cell

Multiple Myeloma

NCT06655519 2024-10-23

An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Phase 1 Not yet recruiting

12 enrolled

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

NCT06500507 2024-07-15

A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma

Phase 1 Not yet recruiting

90 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT05498545 2022-08-12

Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1 Not yet recruiting

34 enrolled

Plasma cell

Multiple Myeloma

NCT05181501 2022-01-06

A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)

Phase 1 Not yet recruiting

20 enrolled

Plasma cell

Multiple Myeloma